Fellow eye anti-VEGF 'crunch' effect in retinopathy of prematurity

Edward H. Wood, Prethy Rao, Stavros N. Moysidis, Vaidehi S. Dedania, Michael J. Elman, Kimberly A. Drenser, Antonio Capone, Michael T. Trese

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


BACKGROUND AND OBJECTIVE: Anti-vascular endothelial growth factor (VEGF) therapy is increasing in popularity for treatment of retinopathy of prematurity (ROP). Despite many technical benefits, issues remain prompting further investigation. PATIENTS AND METHODS: Retrospective case report and literature review. RESULTS: A 42-week-old postmenstrual age female with gestational age of 28 weeks and birth weight of 990 g presented with prominent progression of peripapillary purely tractional atypical stage 4A ROP in both eyes following intravitreal bevacizumab therapy in the right eye only. CONCLUSION: The authors present the first reported case, to their knowledge, of a “crunch” phenomenon tractional retinal detachment from fellow eye administration of bevacizumab.

Original languageEnglish (US)
Pages (from-to)e102-e104
JournalOphthalmic Surgery Lasers and Imaging Retina
Issue number9
StatePublished - Sep 2018

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology


Dive into the research topics of 'Fellow eye anti-VEGF 'crunch' effect in retinopathy of prematurity'. Together they form a unique fingerprint.

Cite this